» Articles » PMID: 19997598

Global MYCN Transcription Factor Binding Analysis in Neuroblastoma Reveals Association with Distinct E-box Motifs and Regions of DNA Hypermethylation

Overview
Journal PLoS One
Date 2009 Dec 10
PMID 19997598
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroblastoma, a cancer derived from precursor cells of the sympathetic nervous system, is a major cause of childhood cancer related deaths. The single most important prognostic indicator of poor clinical outcome in this disease is genomic amplification of MYCN, a member of a family of oncogenic transcription factors.

Methodology: We applied MYCN chromatin immunoprecipitation to microarrays (ChIP-chip) using MYCN amplified/non-amplified cell lines as well as a conditional knockdown cell line to determine the distribution of MYCN binding sites within all annotated promoter regions.

Conclusion: Assessment of E-box usage within consistently positive MYCN binding sites revealed a predominance for the CATGTG motif (p<0.0016), with significant enrichment of additional motifs CATTTG, CATCTG, CAACTG in the MYCN amplified state. For cell lines over-expressing MYCN, gene ontology analysis revealed enrichment for the binding of MYCN at promoter regions of numerous molecular functional groups including DNA helicases and mRNA transcriptional regulation. In order to evaluate MYCN binding with respect to other genomic features, we determined the methylation status of all annotated CpG islands and promoter sequences using methylated DNA immunoprecipitation (MeDIP). The integration of MYCN ChIP-chip and MeDIP data revealed a highly significant positive correlation between MYCN binding and DNA hypermethylation. This association was also detected in regions of hemizygous loss, indicating that the observed association occurs on the same homologue. In summary, these findings suggest that MYCN binding occurs more commonly at CATGTG as opposed to the classic CACGTG E-box motif, and that disease associated over expression of MYCN leads to aberrant binding to additional weaker affinity E-box motifs in neuroblastoma. The co-localization of MYCN binding and DNA hypermethylation further supports the dual role of MYCN, namely that of a classical transcription factor affecting the activity of individual genes, and that of a mediator of global chromatin structure.

Citing Articles

Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?.

Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N Genes Dis. 2025; 12(2):101156.

PMID: 39802403 PMC: 11719324. DOI: 10.1016/j.gendis.2023.101156.


A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma.

Ryl T, Afanasyeva E, Hartmann T, Schwermer M, Schneider M, Schroder C Commun Biol. 2024; 7(1):919.

PMID: 39079981 PMC: 11289481. DOI: 10.1038/s42003-024-06596-6.


Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.

Hofman D, Ruiz-Orera J, Yannuzzi I, Murugesan R, Brown A, Clauser K Mol Cell. 2024; 84(2):261-276.e18.

PMID: 38176414 PMC: 10872554. DOI: 10.1016/j.molcel.2023.12.003.


IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.

Hagemann S, Misiak D, Bell J, Fuchs T, Lederer M, Bley N Mol Cancer. 2023; 22(1):88.

PMID: 37246217 PMC: 10226260. DOI: 10.1186/s12943-023-01792-0.


CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.

Wen Y, Tram V, Chen W, Li C, Yeh H, Thuy Dung P Cell Death Dis. 2023; 14(5):304.

PMID: 37142586 PMC: 10160040. DOI: 10.1038/s41419-023-05836-7.


References
1.
Moon R, Kohn A, De Ferrari G, Kaykas A . WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701. DOI: 10.1038/nrg1427. View

2.
Davidson E, Morris L, Scott I, Rushbrook S, Bird K, Laskey R . Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer. 2003; 88(2):257-62. PMC: 2377046. DOI: 10.1038/sj.bjc.6600729. View

3.
Malynn B, de Alboran I, OHagan R, Bronson R, Davidson L, DePinho R . N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 2000; 14(11):1390-9. PMC: 316670. View

4.
Koppen A, Ait-Aissa R, Koster J, van Sluis P, Ora I, Caron H . Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. Eur J Cancer. 2007; 43(16):2413-22. DOI: 10.1016/j.ejca.2007.07.024. View

5.
Krig S, Jin V, Bieda M, OGeen H, Yaswen P, Green R . Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays. J Biol Chem. 2007; 282(13):9703-9712. PMC: 2269729. DOI: 10.1074/jbc.M611752200. View